201604-0801CI 17. Isshiki T, Sakamoto S, Yamasaki A, et al. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: real-world experience.

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Claims-based prevalence of disease progression among patients with fibrosing interstitial lung disease other than idiopathic pulmonary fibrosis in the United States. Ann Am Thorac Soc. 2022;19(7 ...

prevalence and outcomes between the sexes. According to a ... Researchers Identify Protein Connected to Aging and Idiopathic Pulmonary Fibrosis July 25, 2022 — Idiopathic pulmonary fibrosis (IPF ...

Though oral pirfenidone reduces lung function decline and mortality from idiopathic pulmonary fibrosis (IPF), systemic exposure ... dizziness and dyspnoea, with higher incidence in the 100 mg two ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Pulmonary fibrosis, including its most common form, idiopathic pulmonary fibrosis (IPF), is a progressive and life-threatening condition that results in scarring of the lungs, making it ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.